VIGL Stock: Vigil Neuroscience, Inc. Stock Price, Analysis & Insights
Get live vigl stock price $8.05, comprehensive Vigil Neuroscience, Inc. stock analysis, charts, news, and expert forecast. Real-time vigl stock data and investment insights.
Company Overview
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.
Company Information
- CEO
- Ivana Magovcevic-Liebisch
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 69
Contact Information
- Website
- https://www.vigilneuro.com
- Address
- 1 Broadway
- Country
- US
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 375.71M market capitalization
- Trading Volume: 5.51M shares traded today
- Price Range: 52-week range of $1.31 - $8.10
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for Vigil Neuroscience, Inc.
Vigil Neuroscience, Inc. (VIGL) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 375.71M, the company represents a significant player in its market. The stock is currently trading at $8.05 with a positivedaily change of 0.00%.
The company's 69 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -3.83, beta of 3.34, and 52-week price range from $1.31 to $8.10when evaluating investment opportunities.
Why Invest in Vigil Neuroscience, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Ivana Magovcevic-Liebisch
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.